Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia

Sarandöl, Emre; Dirican, Melahat; AÇIKGÖZ, Hacer Ebru

doi:10.1515/tjb-2018-0377

Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia

Melahat DİRİCAN, (Uludağ Üniversitesi, Biyokimya Anabilim Dalı, Bursa, Türkiye)

Hacer Ebru AÇIKGÖZ, (Uludağ Üniversitesi, Biyokimya Anabilim Dalı, Bursa, Türkiye)

Emre SARANDÖL (Uludağ Üniversitesi, Biyokimya Anabilim Dalı, Bursa, Türkiye)

Türk Biyokimya Dergisi

1 0

Yıl: 2020 Cilt: 45 Sayı: 1 Sayfa Aralığı: 37 - 43 Metin Dili: İngilizce DOI: 10.1515/tjb-2018-0377 İndeks Tarihi: 03-10-2021

Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia

Öz:

Objective: Macroprolactinemia is an important cause of hyperprolactinemia. The aim of this study was to examine the added value of the consideration of modified reference range in determination of macroprolactinemia and true hyperprolactinemia.Materials and methods: Three hundred and ninety patients with high and 131 with normal prolactin (PRL) levels were included in this study. PRL had been analyzed before and after polyethylene glycol precipitation (post-PEG PRL). Recovery percentage (R%) <40% and >60% had been reported as macroprolactinemia and true hyperpro-lactinemia, respectively. Post-PEG PRL levels were evalu-ated according to the modified reference range obtained from those of the normoprolactinemic subjects.Results: According to the R% criterion; macroprol-actinemia had been detected in 24.9% and true hyper-prolactinemia in 67.4% of hyperprolactinemic patients. When the data were evaluated considering the post-PEG PRL levels according to the modified reference range; 13 (13.4%) of the 97 macroprolactinemia reports would be considered as true hyperprolactinemia and 6 (2.3%) of the 263 true hyperprolactinemia reports would be changed as macroprolactinemia.Conclusion: Discrimination capacity of R% criterion for true hyperprolactinemia and macroprolactinemia is lim-ited, and we suggest that, in accordance with R% crite-rion, laboratory reports should include the post-PEG PRL levels along with the modified reference range.

Anahtar Kelime:

Hiperprolaktinemide geri kazanım yüzdesi ve modifiye referans aralık değerlerinin birlikte kullanımı

Öz:

Amaç: Makroprolaktinemi, hiperprolaktineminin önemlibir nedenidir. Bu çalışmanın amacı, makroprolaktinemive gerçek hiperprolaktineminin belirlenmesinde modifiyereferans aralık kullanımının katkısının incelenmesidir. Gereç ve Yöntem: Retrospektif özellikteki bu çalışmayaprolaktin (PRL) düzeyi yüksek olan 390 ve normal olan 131olgu dahil edildi. PRL düzeyi polietilen glikol presipitas- yonundan önce ve hemen sonra (post-PEG PRL) ölçüldü.Geri kazanım yüzdesi (% R) <%40 ve >%60 olanlar sıra-sıyla makroprolaktinemi ve gerçek hiperprolaktinemiolarak rapor edildi. Post-PEG PRL düzeyi, normoprolak- tinemik gruptan elde edilen modifiye referans aralığınagöre değerlendirildi. Bulgular: %R kriterine göre hiperprolaktinemik hastala- rın %24.9’unda makroprolaktinemi ve %67.4’ünde gerçekhiperprolaktinemi saptanmıştır. Veriler, post-PEG PRLseviyeleri dikkate alınarak modifiye referans aralığınagöre yeniden değerlendirildiğinde; makroprolaktinemiolarak rapor edilen 97 olgudan 13’ünün (%13.4) gerçekhiperprolaktinemi olarak ve gerçek hiperprolaktinemi olan 263 olgu raporunun 6’sının (%2.3) makroprolakti- nemi olarak değişmiş olduğu görüldü. Sonuç: Gerçek hiperprolaktinemi ve makroprolaktine- minin ayırımında %R kriteri kısıtlılıklara sahiptir, bunedenle laboratuvar raporlarının %R kriterinin yanı sıra,modifiye referans aralığı ile birlikte post-PEG PRL seviye- lerini de içermesi gerekmektedir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523–631.
2. Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003;92:171–7.
3. Schneider W, Marcovitz S, Al-Shammari S, Yago S, Chevalier S. Reactivity of macroprolactin in common automated immunoassays. Clin Biochem 2001;34:469–73.
4. Germano L, Mormile A, Filtri L, Cocciardi E, Di Grazia M, Marranca D, et al. Evaluation of polyethylene glycol precipitation as screening test for macroprolactinemia using Architect immunoanalyser. Immuno-Anal Biol Spe 2005;20:402–7.
5. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003;49:1504–9.
6. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005;90:3927–32.
7. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 1999;51:119–26.
8. Fahie-Wilson MN, Soule SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34(Pt 3):252–8.
9. Vieira JG, Tachibana TT, Obara LH, Maciel RM. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem 1998;44(8 Pt 1):1758–9.
10. Fahie-Wilson MN. Polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem 1999;45:436–7.
11. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581–8.
12. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001;86:2743–6.
13. Chen YJ, Song GZ, Wang ZN. A new criteria for screening macroprolactinemia using polyethylene glycol treatment combined with different assays for prolactin. Eur Rev Med Pharmacol Sci 2016;20:1788–94.
14. Smith TP, Fahie-Wilson FN. Reporting of post-PEG prolactin concentrations: time to change. Clin Chem 2008;56:484–90.
15. Beltran L, Fahie-Wilson MN, McKenna TJ, Kavanagh L, Smith TP. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008;54:1673–81.
16. Overgaard M, Pedersen SM. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin Chem Lab Med 2017;55:1744–53.
17. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88.
18. Whitehead SJ, Cornes MP, Ford C, Gama R. Reference ranges for serum total and monomeric prolactin for the current generation Abbott Architect assay. Ann Clin Biochem 2015;52(Pt 1):61–6.
19. Bjoro T, Morkrid L, Wergeland R, Turter A, Kvistborg A, Sand T, et al. Frequency of hyperprolactinaemia due to large molecular weight prolactin (150–170 kD PRL). Scand J Clin Lab Invest 1995;55:139–47.
20. Hauache OM, Rocha AJ, Maia AC, Maciel RM, Vieira JG. Screening for macroprolactinaemia and pituitary imaging studies. Clin Endocrinol 2002;57:327–31.
21. Akbulut ED, Ercan M, Erdoğan S, Topçuoğlu S, Yılmaz FM, Turhan T. Assessment of macroprolactinemia rate in a training and research hospital from Turkey. Turk J Biochem 2017;42:87–91.
22. Hattori N, Ishihara T, Saiki Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009;71:702–8.
23. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur J Endocrinol 1994;130:438–45.
24. McCudden CR, Sharpless JL, Grenache DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010;411: 155–60.
25. Beda-Maluga K, Pisarek H, Komorowski J, Swietoslawski J, Fuss-Chmielewska J, Winczyk K. Evaluation of hyperprolactinemia with the use of the intervals for prolactin after macroforms separation. J Physiol Pharmacol 2014;65: 359–64.
26. Chen Y, Wang H, Yang W, Jin W, Yu W, Wang W, et al. A new method of using polyethylene glycol (PEG) precipitation of macroprolactin to detect genuine hyperprolactinemia. J Clin Lab Anal 2016;30:1169–74.

APA	Dirican M, AÇIKGÖZ H, Sarandöl E (2020). Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. , 37 - 43. 10.1515/tjb-2018-0377
Chicago	Dirican Melahat,AÇIKGÖZ Hacer Ebru,Sarandöl Emre Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. (2020): 37 - 43. 10.1515/tjb-2018-0377
MLA	Dirican Melahat,AÇIKGÖZ Hacer Ebru,Sarandöl Emre Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. , 2020, ss.37 - 43. 10.1515/tjb-2018-0377
AMA	Dirican M,AÇIKGÖZ H,Sarandöl E Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. . 2020; 37 - 43. 10.1515/tjb-2018-0377
Vancouver	Dirican M,AÇIKGÖZ H,Sarandöl E Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. . 2020; 37 - 43. 10.1515/tjb-2018-0377
IEEE	Dirican M,AÇIKGÖZ H,Sarandöl E "Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia." , ss.37 - 43, 2020. 10.1515/tjb-2018-0377
ISNAD	Dirican, Melahat vd. "Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia". (2020), 37-43. https://doi.org/10.1515/tjb-2018-0377

APA	Dirican M, AÇIKGÖZ H, Sarandöl E (2020). Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. Türk Biyokimya Dergisi, 45(1), 37 - 43. 10.1515/tjb-2018-0377
Chicago	Dirican Melahat,AÇIKGÖZ Hacer Ebru,Sarandöl Emre Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. Türk Biyokimya Dergisi 45, no.1 (2020): 37 - 43. 10.1515/tjb-2018-0377
MLA	Dirican Melahat,AÇIKGÖZ Hacer Ebru,Sarandöl Emre Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. Türk Biyokimya Dergisi, vol.45, no.1, 2020, ss.37 - 43. 10.1515/tjb-2018-0377
AMA	Dirican M,AÇIKGÖZ H,Sarandöl E Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. Türk Biyokimya Dergisi. 2020; 45(1): 37 - 43. 10.1515/tjb-2018-0377
Vancouver	Dirican M,AÇIKGÖZ H,Sarandöl E Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia. Türk Biyokimya Dergisi. 2020; 45(1): 37 - 43. 10.1515/tjb-2018-0377
IEEE	Dirican M,AÇIKGÖZ H,Sarandöl E "Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia." Türk Biyokimya Dergisi, 45, ss.37 - 43, 2020. 10.1515/tjb-2018-0377
ISNAD	Dirican, Melahat vd. "Evaluation of percentage recoverytogether with modified reference rangein hyperprolactinemia". Türk Biyokimya Dergisi 45/1 (2020), 37-43. https://doi.org/10.1515/tjb-2018-0377